New drug combo targets tough lung cancer mutation
NCT ID NCT03170206
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested two oral drugs, palbociclib and binimetinib, in 34 people with advanced lung cancer that has a specific change in the KRAS gene. The goal was to find the safest dose and see if the combination can slow cancer growth. The study is complete, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Palbociclib and binimetinib (two oral drugs that block cell growth signals)
What this could lead to
If this combination works, it could offer a new treatment option for people with a hard-to-treat form of lung cancer driven by a KRAS mutation.
What could go wrong
This is an early Phase 1 trial with only 34 participants, so it is primarily testing safety and dosing. The drugs may cause side effects and may not shrink tumors or extend life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States